AKRO News
Archived Headlines
- Liver disease biotech Akero Therapeutics prices upsized IPO at $16 high end 06/19/19
- June is getting a flood of biotech IPOs with these 9 deals on the calendar 06/18/19
- US IPO Week Ahead: A biotech wave drives 7 IPOs while Slack targets a direct listing 06/14/19
- Metabolic disease biotech Akero Therapeutics sets terms for $75 million IPO 06/10/19
- NASH biotech Akero Therapeutics files for an $86 million IPO 05/24/19
US IPO Week Ahead: Just 1 biotech is on the calendar in a slow week for the IPO market
After a busy week in the IPO market, just one biotech is scheduled to go public in the week ahead. NASH biotech 89bio (ETNB) plans to raise $85 million at a $225 million market cap. The company’s target indication represents a multi...read more
NASHville: 89bio is the latest biotech IPO targeting liver disease NASH
Backed by OrbiMed and Longitude, Phase 1 biotech 89bio (ETNB) is expected to raise $70 million tonight in the fifth NASH-focused biotech IPO of 2019; insiders have indicated on $40 million (57% of the deal). Another NASH...read more
June's flood of biotech IPOs continues with these 4 deals
June is seeing a wave of biotech IPOs. Five priced last week, and four more are on ...read more
US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public
Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public...read more